1) Indi Molecular is pursuing a hybrid strategy that emphasizes strategic partnerships focused on biological tools, in vivo imaging and therapeutics.

2) PCC’s unsurpassed chemical stability, high chemical selectivity, speed of preparation, low production cost and exact chemical composition confer distinct advantages in each of these fields that molecular antibodies cannot match. Applications range from displacing antibody-dominated techniques in both biological tools and in vitro diagnostics settings, to groundbreaking potential advances in molecular in vivo imaging and targeted therapeutics.

3) The company has a successful partnering history that includes the California Institute of Technology, the Gates Foundation, the United States Department of Defense and a major global pharmaceutical company.

Pipeline Version 2.jpg